Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab long-term safety extension in COPD
MOH_2024-03-03_013291Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of itepekimab in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Sanofi. Primary endpoint: Long-term safety and tolerability. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2024-03-03_013291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-03_013291.